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Background
Cyclic guanosine monophospat (cGMP) is a second mes-
senger activating intracellular protein kinases as part of
the nitric oxide (NO)-cGMP pathway. Fast and reliable
quantification of cGMP is therefore of major importance
for scientific advancement in this field. However, until
now only cumbersome immunoassays for the quantifica-
tion of cGMP are available. Here we present a fast, reliable
and specific method for the quantification of cGMP in
humane plasma by isotope dilution liquid chromatogra-
phy-tandem mass spectrometry (LC-MS/MS).
Methods
For optimal precision and accuracy of the assay, a stable
isotope labeled internal standard has to be provided.
Since such an internal standard is not available commer-
cially, it was synthesized in-house by the conversion of
isotope labeled guanosine triphosphat to isotope labeled
cGMP by the enzyme soluble guanylyl cyclase (sGC), acti-
vated by the NO-donor DEA NONOate.
Plasma sample preparation consisted of the addition of
20 nmol/l of the internal standard, protein precipitation
by the addition of perchloric acid, and extraction of unpo-
lar substances from the aqueous phase with cyclohexane.
The analytes in the aqueous phase were chromatographi-
cally separated by HPLC on a porous graphitic carbon col-
umn and detected by electrospray tandem mass
spectrometry working in the positive ionization mode.
Results
The chromatographic separation resulted in sharp and
symmetrical peaks of cGMP and its stable isotope labeled
internal standard at identical retention times, undisturbed
by interferences from endogenous substances. No mass
spectrometric crosstalk from cGMP to the signal of the
internal standard or vice versa was observed. The extrac-
tion efficiency was determined to 81 ± 6%. The calibration
was linear in the range of 1 to 20 nmol/l. The coefficient
of variation was 6.1% at a concentration of 1 nmol/l and
3.4% at 20 nmol/l with accuracies of -8.5% and -1.6% at
both concentrations, respectively.
First results with this method were achieved in a prelimi-
nary clinical trial enrolling 16 volunteers (age 23 – 55 y,
median 44 years, all male) after giving informed consent.
After oral application of 110 mg/kg arginine, the cGMP
plasma concentrations rose from the baseline of 2.06 ±
0.83 nmol/l to 2.73 ± 1.16 nmol/l after 2 h. The concen-
trations after 4 h and 24 h were back to baseline with 1.92
± 0.74 nmol/l and 2.03 ± 1.12 nmol/l, respectively.
Although not significant, this rise of cGMP fits in the the-
ory that elevated arginine-levels result in higher NO pro-
duction, which in turn leads to more cGMP.
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